phase readout
saveNCT04641442: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
ACTIVE_NOT_RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: Novartis Pharmaceuticals. Phase: PHASE2. Conditions: NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
view source ↗
comments(0)
5-min edit window · permanent after that